You are here: Industry Insights > Sanofi

News List

Sanofi revises immuno-oncology deal with Regeneron pharmaceutical-technology
January 08, 2019
Sanofi and Regeneron Pharmaceuticals have revised a global immuno-oncology discovery and development agreement to develop new treatments for cancer......
Sanofi invests €80M in BioNTech as cancer mRNA hits clinic fiercebiotech
January 07, 2019
Sanofi is set to invest €80 million ($91 million) in BioNTech and extend its cancer collaboration with the German mRNA specialist. The agreement comes as BioNTech and Sanofi prepare to .....
Sanofi and MyoKardia end heart disease drug collaboration pharmatimes
January 04, 2019
Bringing an end to a four-year partnership, Sanofi has terminated its agreement with MyoKardia to jointly develop small-molecule therapeutics, targeting genetic mutations associated with certain heart diseases.
Sanofi offloads drug programmes to MyoKardia and Acer Therapeutics pharmaceutical-technology
January 04, 2019
Sanofi has returned worldwide rights to all programmes that were covered under a licence and collaboration agreement signed with biopharmaceutical company MyoKardia in 2014.
Sanofi, Sema4 launch 5-year, real-world digital asthma study fiercebiotech
January 02, 2019
Sanofi and Sema4 have launched a five-year longitudinal study of nearly 1,200 asthma patients, with plans to incorporate digital tools to develop a better understanding of the disease....
Sanofi blueprints hefty new Boston HQ with massive lease at Cambridge Crossing fiercepharma
December 26, 2018
Sanofi has picked the spot for its Massachusetts headquarters, once again planting its flag squarely in the Kendall Square neighborhood that's the epicenter of biotech on the East Coast.
FDA approves Sanofi/Regeneron’s Dupixent in asthma pharmaphorum
December 21, 2018
The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.
Dengvaxia approved for dengue in EU pharmatimes
December 21, 2018
Dengvaxia will be available in Europe for individuals 9-45 years of age with a documented prior dengue infection, and who are living in endemic areas.
Mylan announces victory over Sanofi in Lantus patent claims pharmaceutical-technology
December 17, 2018
Generic drug maker Mylan has announced that the US Patent and Trademark Appeal Board (PTAB) invalidated Sanofi’s patent infringement claims over insulin drug Lantus......
Mylan says Sanofi loses Lantus insulin patent claims expressbpd
December 14, 2018
Lantus is a long-acting insulin used to treat adults with type 2 diabetes and adults and paediatric patients with type 1 diabetes to control high blood sugar

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page